Jan Schwab is a Neurology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 190 publications with 11,802 citations (h-index 57); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2050 Kenny Rd
Columbus, OH 432213502
Telephone
614-293-4969Provider last certified this registry record 7 Aug 2025.
Clinical trials
- A Study of Autonomic Dynamic Dysfunction to Predict Infections After Spinal Cord Injury.
Sponsor: Ohio State University
- Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury
Sponsor: Jan M. Schwab, MD, PhD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
61.2%Gabapentinoids33%Gabapentin81%Pregabalin19%Part D<11 patientsOther antiepileptics7.9%Topiramate81%Levetiracetam19%Part D<11 patients+ 7 more classes in this area
Musculoskeletal
26.7%gamma-Aminobutyric Acid-ergic Agonist15.8%Baclofen100%Part D≥26 patientsMuscle Relaxant6%Methocarbamol100%Part D≥13 patients+ 2 more classes in this area
Cardiovascular
6.2%Beta blocker3.4%Metoprolol Succinate59%Propranolol Hcl41%Part D<11 patientsCentral alpha-2 Adrenergic Agonist1.5%Clonidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2024 per NIH RePORTER. The latest:
- Protecting endogenous recovery from the "infectious insult" in Spinal Cord Injury
Ohio State University
FY2024$566,089R01NS135237 - Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
Ohio State University
FY2024$356,609R01NS118200 - Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
Ohio State University
FY2023$367,637R01NS118200
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Colleen Cebulla, MD
The Ohio State University Wexner Medical Center
Michael Grever, MD
The Ohio State University Wexner Medical Center
Brad Rovin, MD
The Ohio State University Wexner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”